Background: The benzodiazepine lorazepam is widely utilized in the treatment of elderly individuals with anxiety disorders and related conditions. Negative effects of acute lorazepam administration on cognitive performance, especially memory, have been reported in both previously untreated elderly and in individuals who have received short term (up to three weeks) treatment with therapeutic doses. However, it remains unclear if these adverse cognitive effects also persist after long-term use, which is frequently found in clinical practice. Methods: Cognitively intact elderly individuals (n = 37) on long-term (at least three months) daily treatment with lorazepam were studied using a double-blind placebo-controlled cross-over study design. Subjects were administered their highest daily unit dose of lorazepam (0.25-3.00 mg) or placebo on different days, approximately 1 week apart in a random order, and were assessed on memory, psychomotor speed, and subjective mood states. Results: Subjects had significantly poorer recall and slowed psychomotor performance following acute lorazepam administration. There were no significant effects on self-ratings of mood, sedation, or anxiety in the whole group, but secondary analyses suggested a differential response in subjects with Generalized Anxiety Disorder. Conclusions: The reduced recall and psychomotor slowing that we observed, along with an absence of significant therapeutic benefits, following acute lorazepam administration in elderly long-term users reinforces the importance of cognitive toxicity as a clinical factor in benzodiazepine use, especially in this population.
Introduction
Benzodiazepines (BZPs) are among the most widely prescribed drugs in the rapidly increasing elderly population. A number of surveys indicate that 13%-25% of community-dwelling individuals (aged 65 or over) report current or recent BZP use (Jackson et al., 2014; Lister and File, 1984; Tamblyn et al., 2005; Woods et al., 1992) . However, it is a concern that impairments in multiple cognitive domains (e.g., memory, psychomotor performance) have been demonstrated consistently following acute doses of BZPs, in both healthy and anxious participants (Curran, 1986; Mintzer and Griffiths, 2007; Satzger et al., 1990; Woods et al., 1992) . These impairments have been observed with lorazepam, the BZP frequently recommended for the elderly, due in part to a lack of active metabolites, a relatively shorter elimination half-life, and a presumed better safety profile compared to other BZPs (Tamblyn et al., 2005) .
In the elderly, administration of even a single dose of a BZP impairs performance (Bertz et al., 1997; Nikaido et al., 1990; Pomara et al., 1988 Pomara et al., , 1998 Pomara et al., , 2005 Satzger et al., 1990) , and elderly individuals may show greater sensitivity than younger subjects to the adverse effects of BZPs on psychomotor performance (Bertz et al., 1997; Nikaido et al., 1990; Satzger et al., 1990 ) and memory (Pomara et al., 1989) . Following chronic treatment with BZPs for 1-3 weeks, significant adverse effects can be observed following an acute dose -although partial tolerance may develop (Curran, 1986; Ghoneim et al., 1981; Pomara et al., 1989 Pomara et al., , 1998 . However, clinical treatment often extends beyond 3 weeks (e.g., years), increasing the associated morbidity and mortality (Hampton et al., 2014; Pariente et al., 2008; Tamblyn et al., 2005) . Conversely, discontinuation of BZPs in long-term users is generally associated with an improvement in cognitive function, with no significant adverse effects (Kitajima et al., 2012; Rickels et al., 1999) .
In spite of the prevalence of long-term administration of BZPs, few studies have examined the impact of acute doses of BZPs on cognitive E-mail address: pomara@nki.rfmh.org (N. Pomara).
